HALOZYME THERAPEUT (NASDAQ:HALO)
6.37
0.01 (0.16%)
| HALOZYME THERAPEUT (NASDAQ:HALO) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $6.38 | 52 Week High | $8.09 | ||
| Open | $6.31 | 52 Week Low | $2.60 | ||
| Day High | $6.53 | P/E | N/A | ||
| Day Low | $6.30 | EPS | $-0.76 | ||
| Volume | 394,242 | ||||
| More HALO Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| RMBS | 3 | SUI | 2 |
| CGEN | 2 | ATU | 2 |
| IRE | 1 | EXLS | 1 |
| SNI | 1 | PCBC | 1 |
| KFS | 1 | ISIL | 1 |
| BBEP | 1 | NGSX | 1 |
Entities who have mentioned HALO
- Merriman Curhan Ford | View Related Stories »
- Dividend | View Related Stories »
- Trading Radar | View Related Stories »
- Wedbush Morgan | View Related Stories »
- Lazard | View Related Stories »
- Canaccord Adams | View Related Stories »
- Bain Capital | View Related Stories »
- Brean Murray Carret & Co. | View Related Stories »
- Roth Capital | View Related Stories »
- Jefferies & Co | View Related Stories »
- After-Hours Movers | View Related Stories »
- StreetInsider.com Morning Movers | View Related Stories »
- Unusual 11 Mid-Day Movers | View Related Stories »
- Nonfarm Payrolls | View Related Stories »
View All ReportsStreetInsider.com Reports on HALO
- Halozyme (HALO) posts Q3 Loss of 16c, Beats by 2c
- Trading Radar for 11/06: American International (AIG), Scripps (SNI), Suncor Energy (SU), Blackstone Group (BX) Report
- Halozyme Therapeutics (HALO) Reports Positive Demonstration Showing Faster Insulin Absorption with PH20 Enzyme Concentrations
- Wedbush Morgan Upgrades Halozyme Therapeutics (HALO) to Outperform
- Merriman Curhan Ford Reiterated their Buy on Halozyme (HALO) After Data
View All Press ReleasesCompany Press Releases on HALO
- ProMetic and Halozyme Enter Into Long-Term Supply Agreement
- Halozyme Study Results Demonstrate Significantly Less Absorption Variability for Insulin Lispro Administered with PH20 Enzyme
- Halozyme Therapeutics Reports Third Quarter 2009 Financial Results
- Halozyme to Host Third Quarter Conference Call on November 6 and Present at Two Upcoming Investor Conferences
- Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial with Subcutaneous Herceptin(R)
StreetInsider Reports on HALO by Category
View All BlogsBlogs on HALO
- Halozyme Therapeutics, Inc. Q3 2009 Earnings Call Transcript
- Microsoft breaks out on Q1 release
- Pharma M&A: Big Bonds and Small Deals
- Healthcare Market Movers: SMMX, INSM, ADLS, HEB, ACUR and HALO
- Health Care Market Movers: SMMX, INSM, ADLS, HEB, ACUR and HALO
View All FilingsSEC Filings on HALO
- Form 8-K HALOZYME THERAPEUTICS For: Nov 06
- Form 10-Q HALOZYME THERAPEUTICS For: Sep 30
- Form 8-K HALOZYME THERAPEUTICS For: Sep 30
Comments on recent HALO articles
Comments on HALO
No comments are currently available.
on Feb 26, 2009
at 03:25 PM Halo is very cheap...ready to go up! Halo is unique in Biotech and has so much upswing potential. All Halos eggs aren't in one basket either. Check out the insider trades, very smart directors have invested millions. Time to back up the moving van.
Article: Merriman Curhan Ford Initiates Coverage on Halozyme (HALO) with a Buy